What’s the difference between Ozempic, Wegovy, and Mounjaro?
All three drugs are injectable medications used to help with weight management, but they are not the same medicine.
- Ozempic is semaglutide (a GLP-1 receptor agonist). [1]
- Wegovy is also semaglutide, but it is FDA-approved specifically for chronic weight management. [1]
- Mounjaro is tirzepatide (a dual GIP/GLP-1 receptor agonist). [2]
Because the active ingredients and (in the case of Wegovy) the approval indications differ, results, dosing, and insurance coverage can also differ.
Which one is approved for weight loss (not just diabetes)?
Wegovy is approved for chronic weight management. [1]
Ozempic is semaglutide, but it is primarily known for treating type 2 diabetes (with weight-related effects), and the label/approval for weight management is specific to Wegovy. [1]
Mounjaro (tirzepatide) is a diabetes medication in the information provided here, with weight loss as a major effect rather than the same weight-management approval framing as Wegovy. [2]
How do these drugs work in the body?
- Semaglutide (Ozempic and Wegovy) mimics GLP-1, which helps regulate appetite and food intake. [1]
- Tirzepatide (Mounjaro) activates both GIP and GLP-1 pathways, which can also reduce appetite and support weight loss. [2]
How do they compare for weight loss?
The key practical difference is that Wegovy and Ozempic share the same active drug (semaglutide), while Mounjaro uses a different active drug (tirzepatide). [1][2]
In other words, you’re not comparing “two versions of the same drug” (Ozempic vs Wegovy are the same molecule) so much as comparing:
- Semaglutide (Ozempic/Wegovy) vs
- Tirzepatide (Mounjaro). [1][2]
Are there differences in dosing schedules?
Yes, because the products are different and are used under different prescribing programs. The information provided here identifies the brands and their active ingredients but does not include exact dosing schedules. [1][2]
Who typically gets which medication?
Choice often depends on what you’re treating (weight management vs diabetes), insurance coverage, side-effect tolerance, and clinician judgment. Based on the provided labels/indications, Wegovy is the weight-management-specific option among the three, while Ozempic and Mounjaro are associated here with type 2 diabetes treatment and weight loss as a result. [1][2]
What side effects do people usually worry about?
The provided sources don’t list side effects directly, so I can’t reliably compare them without additional information. If you share what matters most to you (e.g., nausea, reflux, constipation, gallbladder issues, cost, or pregnancy plans), I can tailor a comparison using the relevant label details.
Can you switch between them?
Switching can happen in practice when insurance changes or when someone doesn’t tolerate one medication, but the safest approach depends on the drugs’ different active ingredients and dosing. The provided information doesn’t cover conversion guidance, so it should be handled by a clinician using prescribing instructions. [1][2]
What should you ask your doctor/pharmacist?
- Whether you’re aiming for weight management specifically (which points toward Wegovy among these three) versus diabetes treatment.
- Which active ingredient you’ll use: semaglutide (Ozempic/Wegovy) or tirzepatide (Mounjaro). [1][2]
- What your plan covers and whether prior authorization is required.
---
Sources
[1] https://www.novo-pi.com/wegovy.pdf
[2] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215866